Lexaria Bioscience is testing multiple drug agents using their DehydraTECH (DHT) technology for oral and topical delivery of medications such as GLP-1and CBD. The DehydraTECH is showing substantial improvement in bioabsorption, brain permeation, taste maksing, and side effect reduction.
GLP-1-H24-4 (Phase Ib) Results are promising
Arm breakdowns follow:
➢ Arm 1 – DHT-CBD
➢ Arm 2 – DHT semaglutide
➢ Arm 3 – DHT semaglutide + DHT-CBD
➢ Arm 4 – Rybelsus tablets
➢ Arm 5 – DHT tirzepatide (Control arm)
The DHT semaglutide reduced HgbA1c (long term blood sugar control) and weight in the 8 week trial period, but not as much as Rybelsus. However the DHT semaglutide group lost fat, had less lean muscle loss and less than half the side effects (47% reduction in total adverse events) compared to Rybelsus.
Per Lexaria Bioscience 6/11/25
The two most important strategic objectives of this Study were:
1 – To discover whether DehydraTECH processing of liraglutide would work sufficient to potentially allow for an oral version of the drug to be compared to the current injection-only delivery method; and
2 – To demonstrate comparable functional results to the injected version, which if successful, could allow for an expedited FDA regulatory pathway known as a 505(b)(2) application that is available when an alternate version of a drug (e.g., the dosage form change from injection to oral administration as tested within this Study) retains certain similar performance characteristics as an earlier-approved version of that same drug.
I realize Phase 1b results do not hold a ton of weight, but I think this stock is a bargain and has lots of potential.
-----
Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer: “We want to win the weight loss [battle] but we also want to have a gastrointestinal adverse event profile that is attractive and competitive.”
Have other thoughts on Lexaria Bioscience?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user InvestingNurse holds no position in NasdaqCM:LEXX. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.